



Enzymogen is a biotechnology company developing new drug entities. Main activities: Development of a platform for producing API cannabinoids based on proprietary technology (not plant extracts); Develop cannabinoids as drugs for unmet clinical needs.

Stage: Seed, Pre-Revenues

Industry: Pharmaceutical

Number of Employees: 3

Market Size: Billions
CBG test case have the following uses : Pain, anxiety, Inflammation, digestive conditions, Skin conditions, Glaucoma, Neuroprotection, Antiseptic, Cancer

Investment opportunity: up to \$3M

Use of Proceeds
Enzymogen will use the funds to develop a process that can be applied to produce manufacturing quantities of cannabinoids

Management Team

- Avraham Laban PhD
CEO
- Meir Azulay
Business Development
- Avi Wener
Partner

Active Market Activity
GW Pharma (market cap \$2.567B) has one approved drug and one on the way.

Contact information:
Avraham Laban PhD
avraham@enzymogenbio.com
Yavne, Israel
+972-54-9006252

Enzymogen

Pharmaceutical grade Cannabinoids- API

Investment Opportunity

What we do

Enzymogen develops new drugs for unmet needs based on cannabinoid data, by using its proprietary technology for production of API. The company plans to establish the platform using CBG as a test case and then to develop drugs through pre-clinical and clinical route.

Enzymogen plans to develop drugs either in-house and/or through Joint Ventures.

Need/Opportunity

Cannabinoids are proving to be valuable drug targets, and have generated much interest among pharma companies. Current production methods involve plant extraction which does not produce sufficient yield for manufacturing.

Solution

Enzymogen utilizes biosynthetic and biocatalytic techniques to produce large quantities of a variety of cannabinoids. In addition to manufacturing, our platform will also generate IP that can be licensed to industry players.

Top milestones:

- Experienced management and scientific team
- Networked with top cannabis experts
- Development of biocatalytic proprietary know-how

Competitors

Teewinot

How we are different

Enzymogen utilizes a biosynthetic approach to production

Potential Customers

Enzymogen intends to partner with, license its technology and sell product to pharma companies engaged in cannabinoid drug development. The list includes: GW Pharma, Insys, Cannabis Science and others.

Go To Market

Enzymogen will focus on the production of cannabigerol (CBG) to validate the development model. CBG has wide therapeutic potential and will be an attractive target for pharma. Once the model is proven, we will expand to producing other cannabinoids.

Revenue model

Sales of cannabinoid APIs to pharma companies. Licensing and royalty agreements